Statin Therapy in Young Adult Survivors of Childhood Cancer

This study is currently recruiting participants.
Verified January 2014 by University of Minnesota - Clinical and Translational Science Institute
Sponsor:
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier:
NCT01733953
First received: November 20, 2012
Last updated: January 10, 2014
Last verified: January 2014

November 20, 2012
January 10, 2014
November 2012
November 2014   (final data collection date for primary outcome measure)
Change From Baseline in Brachial Artery Flow-Mediated Dilation at 6-months [ Time Frame: Baseline and 6-Months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01733953 on ClinicalTrials.gov Archive Site
  • Change from Baseline in Carotid Artery Compliance at 6-Months [ Time Frame: Baseline and 6-Months ] [ Designated as safety issue: No ]
  • Change from Baseline in Carotid Artery Distensibility at 6-Months [ Time Frame: Baseline and 6-Months ] [ Designated as safety issue: No ]
  • Change from Baseline in Pulse Wave Velocity at 6-Months [ Time Frame: Baseline and 6-Months ] [ Designated as safety issue: No ]
  • Change from Baseline in Augmentation Index at 6-Months [ Time Frame: Baseline and 6-Months ] [ Designated as safety issue: No ]
  • Change from Baseline in Carotid Intima-Media Thickness at 6-Months [ Time Frame: Baseline and 6-Months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Statin Therapy in Young Adult Survivors of Childhood Cancer
Pilot Study of Statin Therapy in Young Adult Survivors of Childhood Cancer

Adult survivors of childhood cancer are at high risk of developing cardiovascular disease. Therapies used to treat many cancers, such as chemotherapy and radiation, likely cause damage to the surface of the artery wall called the endothelial layer, leading to the induction of atherosclerosis and eventual cardiovascular disease. HMG coenzyme A reductase inhibitors, or statins, improve endothelial function independent of cholesterol-lowering. In addition, statins have been shown to reduce arterial stiffness and slow arterial thickening. Despite strong evidence supporting the vascular benefits of statins in many different patient populations, these medications have never been studied in cancer survivors. Therefore, the overall objective of this study is to evaluate the effects of statin therapy on vascular health in young adult survivors of childhood cancer.

Twenty-four young adult (age 18-39 years old) survivors of childhood acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma (NHL) will be enrolled in a six-month randomized, double-blind (participants and investigators), placebo-controlled pilot clinical trial comparing the effects of atorvastatin versus placebo on endothelial function and other measures of vascular health.

Our primary objective is to evaluate the effects of 6-months of statin therapy on conduit artery endothelial function in young adult survivors of childhood cancer. The investigators hypothesize that, compared to placebo, atorvastatin will significantly increase brachial artery flow-mediated dilation in survivors of childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.

Adult survivors of childhood cancer are at seven times the risk of dying from cardiovascular disease compared to the general population. The increased risk is thought to be the result of the therapies used to treat the cancer such as chemotherapy and radiation. These therapies likely cause damage to the endothelial cells, which line the arterial wall and, when function properly, offer protection from atherosclerosis. Young adult survivors of childhood ALL have reduced endothelial function, or endothelial dysfunction, compared to healthy controls. Endothelial dysfunction is considered an early manifestation of atherosclerosis and therefore is an ideal target of therapy in order to reduce the risk of cardiovascular disease. Interventions that improve endothelial function in young adult survivors of childhood cancer may be beneficial in terms of mitigating the medium- and long-term risk of developing this chronic disease.

HMG coenzyme A reductase inhibitors, or statins, are widely used for cardiovascular disease risk reduction. These medications are primarily used to reduce levels of total- and low-density lipoprotein (LDL) -cholesterol. Meta-analyses have consistently demonstrated that statin therapy improves endothelial function in a wide array of patient populations. Beyond their well-described vascular benefits, statins are an attractive therapeutic option for cardiovascular disease risk reduction due to their strong safety profile.

Despite the clear potential for endothelial function improvement and cardiovascular risk reduction, statin therapy has never been evaluated in survivors of childhood cancer. Although statins have been well-studied in other patient populations at risk for cardiovascular disease, there is strong justification for evaluation in cancer survivors since the mechanisms responsible for the vascular problems in these individuals (treatment-induced vascular toxicity) differ from traditional atherosclerosis. Therefore, the objective of the current study is to assess the ability of statin therapy to improve endothelial function, arterial stiffness, and arterial thickening in young adult survivors of childhood cancer. The focus of the study will be on survivors of hematologic malignancies, acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL), since the former has been shown to be associated with endothelial impairments and both cancers share common treatment exposures (chemotherapy and radiation), which is likely the primary factor responsible for endothelial dysfunction in these individuals.

Twenty-four young adult (age 18-39 years old) survivors of childhood acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL)will be enrolled in a six-month randomized, double-blind (participants and investigators), placebo-controlled pilot clinical trial comparing the effects of atorvastatin versus placebo on endothelial function and other measures of vascular health. Following baseline testing, subjects will be randomly assigned (1:1) to either atorvastatin or placebo. Participants will return at 1-month and 3-months for assessment of safety (blood draw and adverse event assessment) and medication compliance and at 6-months for assessment of safety, medication compliance, and reassessment of baseline variables.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Cardiovascular Disease
  • Childhood ALL
  • Childhood NHL
  • Drug: Atorvastatin
    6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.
    Other Name: Lipitor
  • Drug: Sugar Pill (Placebo)
    6-Months of placebo (sugar) pill; oral, once daily
    Other Name: Placebo
  • Experimental: Atorvastatin
    6-Months Atorvastatin Therapy; 40mg oral, once daily
    Intervention: Drug: Atorvastatin
  • Placebo Comparator: Sugar Pill (Placebo)
    6-Months Placebo (sugar pill); oral, once daily
    Intervention: Drug: Sugar Pill (Placebo)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
24
November 2014
November 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Survivor of childhood acute lymphoblastic leukemia (ALL) or non-Hodgkins's lymphoma (NHL) (treated for ALL or NHL before the age of 21 years old and ≥5 years post-treatment)
  • 18-39 years old

Exclusion Criteria:

  • Type 1 or 2 diabetes mellitus
  • Prior treatment with hematopoietic stem cell transplant
  • Low-density lipoprotein (LDL) -cholesterol ≥130 mg/dL (individuals with elevated LDL-cholesterol will be referred for clinical management of dyslipidemia)
  • Alanine transaminase (ALT), Aspartate transaminase (AST), or Creatine kinase (CK) greater than 2 times the upper limit of normal
  • Current or recent (within 6-months) use of lipid-lowering medication
  • Recent initiation (within 6-months) of anti-hypertensive medication (individuals on stable therapy may be enrolled)
  • Current or recent (within 6-months) use of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine or strong CYP3A4 inhibitors (i.e. clarithromycin, HIV protease inhibitors, and itraconazole)
  • Pregnant, lactating or planning to become pregnant
  • Liver/renal dysfunction
Both
18 Years to 39 Years
No
Contact: Cameron E Naughton, MPA 612-625-3623 naug0009@umn.edu
United States
 
NCT01733953
1207M17202
Yes
University of Minnesota - Clinical and Translational Science Institute
University of Minnesota - Clinical and Translational Science Institute
Not Provided
Principal Investigator: Aaron S Kelly, Ph.D. University of Minnesota - Clinical and Translational Science Institute
University of Minnesota - Clinical and Translational Science Institute
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP